MIRM
Price
$73.53
Change
-$0.89 (-1.20%)
Updated
Oct 17 closing price
Capitalization
3.69B
25 days until earnings call
Intraday Buy/Sell Signals
RIGL
Price
$27.94
Change
-$0.17 (-0.60%)
Updated
Oct 17 closing price
Capitalization
501.17M
Intraday Buy/Sell Signals
Interact to see
Advertisement

MIRM vs RIGL

Header iconMIRM vs RIGL Comparison
Open Charts MIRM vs RIGLBanner chart's image
Mirum Pharmaceuticals
Price$73.53
Change-$0.89 (-1.20%)
Volume$351.13K
Capitalization3.69B
Rigel Pharmaceuticals
Price$27.94
Change-$0.17 (-0.60%)
Volume$383.57K
Capitalization501.17M
MIRM vs RIGL Comparison Chart in %
MIRM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RIGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MIRM vs. RIGL commentary
Oct 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MIRM is a Hold and RIGL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 18, 2025
Stock price -- (MIRM: $73.53 vs. RIGL: $27.94)
Brand notoriety: MIRM and RIGL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MIRM: 46% vs. RIGL: 55%
Market capitalization -- MIRM: $3.69B vs. RIGL: $501.17M
MIRM [@Biotechnology] is valued at $3.69B. RIGL’s [@Biotechnology] market capitalization is $501.17M. The market cap for tickers in the [@Biotechnology] industry ranges from $106.87B to $0. The average market capitalization across the [@Biotechnology] industry is $2.06B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MIRM’s FA Score shows that 1 FA rating(s) are green whileRIGL’s FA Score has 1 green FA rating(s).

  • MIRM’s FA Score: 1 green, 4 red.
  • RIGL’s FA Score: 1 green, 4 red.
According to our system of comparison, both MIRM and RIGL are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MIRM’s TA Score shows that 3 TA indicator(s) are bullish while RIGL’s TA Score has 5 bullish TA indicator(s).

  • MIRM’s TA Score: 3 bullish, 3 bearish.
  • RIGL’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, RIGL is a better buy in the short-term than MIRM.

Price Growth

MIRM (@Biotechnology) experienced а +1.13% price change this week, while RIGL (@Biotechnology) price change was -0.85% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.56%. For the same industry, the average monthly price growth was +15.88%, and the average quarterly price growth was +79.09%.

Reported Earning Dates

MIRM is expected to report earnings on Nov 12, 2025.

Industries' Descriptions

@Biotechnology (+1.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MIRM($3.69B) has a higher market cap than RIGL($501M). MIRM YTD gains are higher at: 77.823 vs. RIGL (66.112). RIGL has higher annual earnings (EBITDA): 109M vs. MIRM (-18.79M). MIRM has more cash in the bank: 305M vs. RIGL (108M). RIGL has less debt than MIRM: RIGL (61M) vs MIRM (319M). MIRM has higher revenues than RIGL: MIRM (429M) vs RIGL (268M).
MIRMRIGLMIRM / RIGL
Capitalization3.69B501M737%
EBITDA-18.79M109M-17%
Gain YTD77.82366.112118%
P/E RatioN/A5.15-
Revenue429M268M160%
Total Cash305M108M282%
Total Debt319M61M523%
FUNDAMENTALS RATINGS
MIRM vs RIGL: Fundamental Ratings
MIRM
RIGL
OUTLOOK RATING
1..100
6651
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
53
Fair valued
PROFIT vs RISK RATING
1..100
687
SMR RATING
1..100
968
PRICE GROWTH RATING
1..100
3941
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RIGL's Valuation (53) in the Biotechnology industry is in the same range as MIRM (58) in the null industry. This means that RIGL’s stock grew similarly to MIRM’s over the last 12 months.

MIRM's Profit vs Risk Rating (6) in the null industry is significantly better than the same rating for RIGL (87) in the Biotechnology industry. This means that MIRM’s stock grew significantly faster than RIGL’s over the last 12 months.

RIGL's SMR Rating (8) in the Biotechnology industry is significantly better than the same rating for MIRM (96) in the null industry. This means that RIGL’s stock grew significantly faster than MIRM’s over the last 12 months.

MIRM's Price Growth Rating (39) in the null industry is in the same range as RIGL (41) in the Biotechnology industry. This means that MIRM’s stock grew similarly to RIGL’s over the last 12 months.

MIRM's P/E Growth Rating (100) in the null industry is in the same range as RIGL (100) in the Biotechnology industry. This means that MIRM’s stock grew similarly to RIGL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MIRMRIGL
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
79%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
74%
Momentum
ODDS (%)
Bullish Trend 2 days ago
87%
N/A
MACD
ODDS (%)
N/A
Bullish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 4 days ago
76%
Bullish Trend 4 days ago
83%
Declines
ODDS (%)
Bearish Trend 2 days ago
65%
Bearish Trend 6 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
68%
Bullish Trend 2 days ago
84%
Aroon
ODDS (%)
Bearish Trend 2 days ago
57%
Bearish Trend 2 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
MIRM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RIGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JVTNX90.720.05
+0.06%
Janus Henderson Venture N
BIAFX43.59N/A
N/A
Brown Advisory Flexible Equity Inv
QBNAX34.94N/A
N/A
Pear Tree Polaris Small Cap Instl
TVRVX26.07N/A
N/A
Third Avenue Real Estate Value Investor
FZROX23.13N/A
N/A
Fidelity ZERO Total Market Index